Forecasting and Ordering. Throughout the Term of this Contract, on a monthly basis commencing on the Effective Date, the Owner will provide the Vendor with rolling twelve-month forecasts of its ongoing Product and Service requirements. Such forecasts will, to the extent applicable, include, but not be limited to, the Owner's Site Acquisition, Switch Site Ready Date, Network Interconnection and Microwave Relocation progress to such date. Upon the review and reasonable acceptance of such forecasts by the Vendor pursuant to the terms of this Contract, the Owner will have the right, but not the obligation, to confirm to the Vendor its orders for the Products and Services set forth in such forecasts pursuant to the Owner's delivery to the Vendor of formal written orders specifying the Products and/or Services to be purchased in connection with the terms of this Contract. The Vendor's obligation to deliver in accordance with accepted forecasts will be subject to receipt of the Owner's orders in accordance with the applicable ordering procedures. If the Owner fails to deliver any forecast pursuant to this subsection 2.37 for any reason, the Vendor will be responsible for asking the Owner to actually deliver such forecast to the extent it requires such forecast at such time.
Forecasting and Ordering. 60 2.38 Microwave Relocation; Network Interconnection.............. 60 2.39 Vendor To Inform Itself Fully; Waiver of Defense........... 61 2.40 CMI/HIC.................................................... 61 2.41 Site Acquisition Delay Testing............................. 61
Forecasting and Ordering. A Service Provider must submit forecasts to NBI outlining the location and type of Physical Co- Location they wish to order. This should be in the form of a 12-month rolling forecast, submitted on a quarterly basis. Full details on the forecasting process is available in the Co-Location Process Manual, available on the NBI website or directly from the NBI Account Manager. Requests for Co-Location space outside the forecast will be treated on a case-by-case basis.
Forecasting and Ordering. (a) No later than the first (1st) day of each calendar quarter, Forty Seven shall supply Lonza with a written forecast showing Forty Seven’s good faith estimated quarterly Commencement Date requirements for Batches to be manufactured within the Assigned Capacity at Lonza’s Facility and any Additional cGMP Batches (as defined below) requested by Forty Seven to be manufactured at Lonza’s Facility in the following [*] month period or the remainder of the Term, whichever is less (the “Forecast”). No later than [*] days following Lonza’s receipt of a Forecast, Lonza shall provide written notice to Forty Seven of whether it has (as of the date of receipt of the Forecast) capacity available to manufacture the number of Batches forecasted therein in accordance with the schedule proposed by Forty Seven and shall provide Forty Seven with an estimated production schedule showing the estimated Commencement Date and estimated delivery date of each Batch (“Forecast Response”). The forecast and notice of available capacity given in this Clause 6.3 shall not be binding on Forty Seven or Lonza, except as otherwise set forth in Clause 6.1. For the avoidance of doubt, no notice from Lonza to Forth Seven provided pursuant to this Clause 6.3 shall relieve Lonza of its obligations under Clause 6.1, except as permitted by Clause 6.4.
(b) Forty Seven may place firm purchase orders for its requirement for Additional cGMP Batches at least [*] months prior to the desired Commencement Date of each such Batch unless otherwise mutually agreed. Lonza shall accept or reject Forty Seven’s orders for Additional cGMP Batches within [*] calendar days of Lonza’s receipt of the purchase order; provided that if Lonza fails to accept or reject a purchase order within such [*] calendar day period, [*]. Lonza shall use commercially reasonable efforts to accept all purchase orders submitted by Forty Seven in accordance with this Section 6.3(b). Each accepted purchase order is a “Binding Purchase Order.” All Binding Purchase Orders shall be subject to the cancellation provisions in Clause 6.5.
Forecasting and Ordering. 2.1 Sativex BDP will be ordered by Novartis against a rolling forecast, with details of firm order periods and other related matters to be contained in the Manufacturing and Supply Agreement.
2.2 In addition, Novartis will have the ability to request GW to provide Additional Services from time to time. The fee for providing Additional Services will be agreed on a case by case basis.
Forecasting and Ordering. Philips shall issue to Diametrics a monthly written, rolling, non-binding six (6) month forecast of its purchase of Portal Measurement Products. Such forecasts shall be updated monthly. Philips shall issue binding written purchase orders for Portal Measurement Products at least sixty (60) days prior to the proposed shipping date for such items. All purchase orders in excess of Philips' forecast shall be subject to written acceptance by Diametrics. Diametrics will use reasonable efforts to supply such items in a timely fashion, subject to Diametrics' reasonable production capabilities and provided that such purchase orders are consistent with Philips' forecasts.
Forecasting and Ordering. Prometheus shall purchase from AstraZeneca or its designee, its entire requirements of the Product for sale by Prometheus in the Territory pursuant to this Agreement at the Purchase Price determined in accordance with Article 13 (Purchase Price, Invoicing and Payment).
Forecasting and Ordering. Within thirty (30) days following identification of the Products in Exhibit A, NeoGenomics shall provide Abbott with a written good faith forecast for quantities of Products required by NeoGenomics for the subsequent twelve (12) month period. The forecast shall be a rolling annual forecast and it shall be updated by NeoGenomics at least ten (10) days before the end of each Calendar Quarter and shall provide NeoGenomics’ forecasted requirements of Products for the subsequent twelve (12) month period. The first three (3) months of each such forecast shall constitute a firm purchase order for Products. The last nine (9) months of each forecast shall not be binding on either party and shall be used for planning purposes and safety stock building. In any Calendar Year, NeoGenomics will not issue a forecast for, or order, a greater quantity of Products than NeoGenomics reasonably believes will be necessary to fulfill its anticipated needs for the Melanoma LDT during such Calendar Year. If Abbott reasonably believes that NeoGenomics has ordered Products in excess of the foregoing limitation, Abbott reserves the right to adjust the applicable purchase order to withhold shipment of such excess quantities.
Forecasting and Ordering. No later than the [***], Customer shall supply Lonza with a [***] forecast showing Customer’s good faith estimated [***] requirements for Batches for at a minimum the following [***] period (the “Forecast”). No later than [***] days following Lonza’s receipt of a Forecast, Lonza shall provide written notice to Customer of whether it has (as of the date of receipt of the Forecast) capacity available to manufacture the number of Batches forecasted therein and shall provide Customer with an estimated production schedule showing the estimated Commencement Date and delivery date of each Batch. The first [***] of any Forecast shall be binding (“Binding Forecast”). Binding purchase orders (“Purchase Orders”) for the entire [***] shall be submitted by Customer on the basis of the Binding Forecast within [***] business days after receipt of Lonza’s estimated Commencement Data and delivery date of each Batch. No Forecast shall amend any previous Binding Forecast. In order to ensure optimal production planning, Customer will use its best efforts to reach an accuracy of [***] of the non-binding portion of any Forecast.
Forecasting and Ordering. Oncogenerix shall supply a rolling twelve (12) month forecast of its estimated requirements for the Licensed Products to be updated on a quarterly basis detailing final confirmation of Oncogenerix’s requirements for the Licensed Products for the following three (3) months.
